ArrowMark Colorado Holdings LLC increased its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 13.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,394,947 shares of the company's stock after acquiring an additional 169,250 shares during the quarter. ArrowMark Colorado Holdings LLC owned approximately 1.32% of MaxCyte worth $5,426,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of MaxCyte by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 5,347,112 shares of the company's stock worth $22,404,000 after purchasing an additional 65,004 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of MaxCyte by 20.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company's stock valued at $106,000 after acquiring an additional 4,320 shares during the period. Chevy Chase Trust Holdings LLC increased its stake in shares of MaxCyte by 2.0% during the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 1,322,560 shares of the company's stock worth $5,184,000 after purchasing an additional 26,163 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of MaxCyte by 24.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 423,209 shares of the company's stock worth $1,659,000 after purchasing an additional 83,025 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of MaxCyte by 22.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company's stock worth $128,000 after purchasing an additional 5,927 shares during the period. Hedge funds and other institutional investors own 68.81% of the company's stock.
Insider Transactions at MaxCyte
In other news, Director Stanley C. Erck sold 29,767 shares of the stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total transaction of $118,174.99. Following the transaction, the director now directly owns 269,118 shares in the company, valued at approximately $1,068,398.46. This represents a 9.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 57,374 shares of company stock valued at $220,957 in the last quarter. Insiders own 3.00% of the company's stock.
MaxCyte Stock Performance
NASDAQ:MXCT traded down $0.10 during trading hours on Tuesday, reaching $3.53. The stock had a trading volume of 257,054 shares, compared to its average volume of 533,443. The stock has a market cap of $372.34 million, a P/E ratio of -10.68 and a beta of 1.37. The stock has a 50 day simple moving average of $3.67 and a 200 day simple moving average of $4.11. MaxCyte, Inc. has a 12-month low of $3.16 and a 12-month high of $5.55.
MaxCyte (NASDAQ:MXCT - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The business had revenue of $8.16 million during the quarter, compared to analyst estimates of $7.50 million. During the same period in the previous year, the business earned ($0.11) EPS. On average, equities analysts expect that MaxCyte, Inc. will post -0.43 earnings per share for the current fiscal year.
MaxCyte Profile
(
Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Further Reading
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
